{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:33:46Z","timestamp":1786660426981,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3791-z","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T09:03:28Z","timestamp":1550739808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience"],"prefix":"10.1186","volume":"19","author":[{"given":"Leonard B.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthakrishnan","family":"Ramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Guervil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"3791_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2106\/JBJS.N.01350","volume":"97","author":"HM Kremers","year":"2015","unstructured":"Kremers HM, Nwojo ME, Ransom JE, et al. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Joint Surg Am. 2015;97:837\u201345.","journal-title":"J Bone Joint Surg Am"},{"key":"3791_CR2","first-page":"1027","volume":"84","author":"J Hatzenbuehler","year":"2011","unstructured":"Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84:1027\u201333.","journal-title":"Am Fam Physician"},{"key":"3791_CR3","first-page":"CD004439","volume":"9","author":"LO Conterno","year":"2013","unstructured":"Conterno LO, Turchi MD. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2013;9:CD004439.","journal-title":"Cochrane Database Syst Rev"},{"key":"3791_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","volume":"364","author":"DP Lew","year":"2004","unstructured":"Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369\u201379.","journal-title":"Lancet"},{"key":"3791_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/pmj.76.898.479","volume":"76","author":"J Ciampolini","year":"2000","unstructured":"Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J. 2000;76:479\u201383.","journal-title":"Postgrad Med J"},{"key":"3791_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1086\/380449","volume":"38","author":"BA Lipsky","year":"2004","unstructured":"Lipsky BA, Itani K, Norden C, linezolid diabetic foot infections study group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam\/amoxicillin-clavulanate. Clin Infect Dis. 2004;38:17\u201324.","journal-title":"Clin Infect Dis"},{"key":"3791_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1056-8727(99)00065-3","volume":"13","author":"M Eneroth","year":"1999","unstructured":"Eneroth M, Larsson J, Apelqvist J. Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J Diabetes Complicat. 1999;13:254\u201363.","journal-title":"J Diabetes Complicat"},{"key":"3791_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/cir842","volume":"54","author":"B Spellberg","year":"2012","unstructured":"Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54:393\u2013407.","journal-title":"Clin Infect Dis"},{"key":"3791_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/jac\/dkg186","volume":"51","author":"AD Tice","year":"2003","unstructured":"Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother. 2003;51:1261\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"3791_CR10","unstructured":"Teflaro\u00ae (ceftaroline fosamil). Full Prescribing Information, Allergan plc, Dublin, Ireland, 2016."},{"key":"3791_CR11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1128\/AAC.00019-10","volume":"54","author":"K Kosowska-Shick","year":"2010","unstructured":"Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54:1670\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"3791_CR12","unstructured":"Riccobene T, Cole P, Wolferstetter E, et al. Penetration of ceftaroline (CPT) into bone following administration of ceftaroline fosamil (CPT-F) to subjects undergoing total hip replacement surgery. Presented at: 54th Interscience conference on antimicrobial agents and chemotherapy, September 5\u20139, 2014; Washington, DC."},{"key":"3791_CR13","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","volume":"65","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65:iv41\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"3791_CR14","doi-asserted-by":"publisher","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","volume":"65","author":"MH Wilcox","year":"2010","unstructured":"Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65:iv53\u201365.","journal-title":"J Antimicrob Chemother"},{"key":"3791_CR15","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1128\/AAC.00149-08","volume":"52","author":"Y Ge","year":"2008","unstructured":"Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:3398\u2013407.","journal-title":"Antimicrob Agents Chemother"},{"key":"3791_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/IPC.0b013e31825b2110","volume":"21","author":"R Watkins","year":"2013","unstructured":"Watkins R. Successful treatment of osteomyelitis from methicillin-resistant Staphylococcus aureus with ceftarolin. Infect Dis Clin Pract. 2013;21:48\u20139.","journal-title":"Infect Dis Clin Pract"},{"key":"3791_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/IPC.0b013e318276959f","volume":"21","author":"H Zainah","year":"2013","unstructured":"Zainah H, Hammoud M, Vazquez JA. Use of ceftaroline in the management of vertebral osteomyelitis. Infect Dis Clin Pract. 2013;21:269\u201371.","journal-title":"Infect Dis Clin Pract"},{"key":"3791_CR18","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/AAC.02371-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"3791_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/dmrr.2624","volume":"31","author":"BA Lipsky","year":"2015","unstructured":"Lipsky BA, Cannon CM, Ramani A, et al. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience. Diabetes Metab Res Rev. 2015;31:395\u2013401.","journal-title":"Diabetes Metab Res Rev"},{"key":"3791_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","volume":"23","author":"JA Vazquez","year":"2015","unstructured":"Vazquez JA, Maggiore CR, Cole P, et al. Ceftaroline fosamil for the treatment of bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2015;23:39\u201343.","journal-title":"Infect Dis Clin Pract"},{"key":"3791_CR21","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1128\/AAC.00498-15","volume":"59","author":"JA Justo","year":"2015","unstructured":"Justo JA, Mayer SM, Pai MP, et al. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Antimicrob Agents Chemother. 2015;59:3956\u201365.","journal-title":"Antimicrob Agents Chemother"},{"key":"3791_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/655827","volume":"51","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641\u201350.","journal-title":"Clin Infect Dis"},{"key":"3791_CR23","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/657313","volume":"51","author":"TM File Jr","year":"2010","unstructured":"File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51:1395\u2013405.","journal-title":"Clin Infect Dis"},{"key":"3791_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/phar.1435","volume":"34","author":"R Jain","year":"2014","unstructured":"Jain R, Chan JD, Rogers L, et al. High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy. 2014;34:758\u201363.","journal-title":"Pharmacotherapy"},{"key":"3791_CR25","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2146\/ajhp130474","volume":"71","author":"FK Yam","year":"2014","unstructured":"Yam FK, Kwan BK. A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline. Am J Health Syst Pharm. 2014;71:1457\u201361.","journal-title":"Am J Health Syst Pharm"},{"key":"3791_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/jcpt.12062","volume":"38","author":"RH Rimawi","year":"2013","unstructured":"Rimawi RH, Frenkel A, Cook PP. Ceftaroline - a cause for neutropenia. J Clin Pharm Ther. 2013;38:330\u20132.","journal-title":"J Clin Pharm Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3791-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3791-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3791-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T19:08:08Z","timestamp":1582225688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3791-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3791"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3791-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"1 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was submitted to and approved by appropriate institutional review boards (IRBs) as listed in Additional file : Table S1. This study was conducted in compliance with the International Conference on Harmonisation (ICH) Technical Requirements for Registration of Pharmaceuticals for Human Use: Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance (1996), Good Pharmacoepidemiology Practice, Health Insurance Portability and Accountability Act, 21 CFR Part 11, and any additional national or IRB requirements. Due to the retrospective nature of data collection for this study, patient written consent was waived or collected before data extraction as appropriate based on individual site IRB requirements <b>(<\/b>Additional file : Table S1<b>)<\/b>.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; individual patient data are not presented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors. LBJ has received research support from Allergan. AR has served as a speaker for Allergan and Gilead. DJG has received clinical research support from Durata Therapeutics Inc. (now Allergan plc).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"183"}}